Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (9), 1567-71

The Effect of PPI Use on Human Gut Microbiota and Weight Loss in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass

Affiliations

The Effect of PPI Use on Human Gut Microbiota and Weight Loss in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass

Emily K Ward et al. Obes Surg.

Abstract

Laparoscopic Roux-en-Y gastric bypass (LRYGB) achieves sustainable weight loss possibly by altering the gut microbiota. The effect of a proton pump inhibitor (PPI) on weight loss and the gut microbiota has not been explored. PPI use and the gut microbiota were assessed before and 6 months after LRYGB in eight patients. Bacterial profiles were generated by 16S ribosomal RNA (rRNA) gene sequencing. Prior to LRYGB, PPI users had a higher percent relative abundance (PRA) of Firmicutes compared to nonusers. PPI users at 6 months post-LRYGB had a higher PRA of Firmicutes [48.6 versus 35.6%, p = nonsignificant (NS)] and a trend toward significantly lower percent excess weight loss (49.3 versus 61.4%, p = 0.067) compared to nonusers. PPI use post-LRYGB may impair weight loss by modifying gut microbiota.

Similar articles

See all similar articles

Cited by 15 PubMed Central articles

See all "Cited by" articles

References

    1. Bioinformatics. 2012 Jul 15;28(14):1823-9 - PubMed
    1. Appl Environ Microbiol. 2011 May;77(10):3219-26 - PubMed
    1. Science. 2013 Mar 1;339(6123):1084-8 - PubMed
    1. Am J Gastroenterol. 2008 Aug;103(8):2111-22 - PubMed
    1. Pharmacogenomics J. 2013 Dec;13(6):514-22 - PubMed

Publication types

MeSH terms

Feedback